| 
						
						
						 Israel 
						cabinet expected to approve medical cannabis exports 
   Send a link to a friend 
		[January 24, 2019] 
		 JERUSALEM (Reuters) - 
		Israel's cabinet is set to approve a long-awaited law to allow exports 
		of medical cannabis, the Finance Ministry said on Wednesday, in a move 
		likely to boost state revenues. | 
        
            | 
			
			 The ministry said the bill, to be voted on at Sunday's cabinet 
			meeting, allows the export of medical cannabis to countries that 
			permit its use after receiving licences from the health regulator. 
 "The bill is expected to open a new market for Israeli producers, 
			which is expected to increase investment in the fields of 
			agriculture, research and production, and create new jobs," the 
			ministry said.
 
 Parliament last month gave final approval to the law, but it still 
			needs approval from cabinet ministers and Prime Minister Benjamin 
			Netanyahu.
 
			 
			Some lawmakers had tried to block the legislation of Israeli-grown 
			cannabis going abroad, fearing more cultivation could push more 
			drugs onto the streets at home.
 Israeli companies -- benefiting from a favorable climate and 
			expertise in medical and agricultural technologies -- are among the 
			world's biggest producers of medical cannabis.
 
			
            [to top of second column] | 
 
			The government estimate exports could raise tax revenue by 1 billion 
			shekels ($272 million). At the same time, the bill imposes tough 
			regulations on exporters and threatens jail terms and hefty fines 
			for violations.
 Eight companies cultivate cannabis in Israel, many of which have 
			opened farms abroad to get into the international market. Dozens of 
			business owners have requested government authorization to export.
 
 ($1 = 3.6812 shekels)
 
 (Reporting by Steven Scheer, editing by Larry King)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |